CDC closed near $77.19 in mid-November 2026, holding within a few percentage points of its 52-week high after a steady recovery from a late-September dip. The fund's 52-week range of roughly $64.30 to $78.48 reflects a broader uptrend for high-dividend, low-volatility large-cap equities over the past year. In the most recent 30 days, the fund added about 3.5%, a measured advance consistent with its defensive, income-focused profile. Trading volume remains modest and in line with the fund's typical daily average, suggesting stable rather than speculative positioning among investors.
CDC seeks investment results that correspond to the Nasdaq Victory U.S. Large Cap 100 High Dividend Long/Cash Volatility Weighted Index. The underlying methodology identifies the 100 highest dividend-yielding stocks within the Nasdaq Victory U.S. Large Cap 500 Volatility Weighted Index and assigns greater weight to lower-volatility names, creating a portfolio tilted toward stable, income-producing companies. The fund, which launched in July 2014 and is managed by Victory Capital Management, typically invests at least 80% of its assets in the index's securities.
The portfolio's sector exposure is dominated by Financials (roughly 24%) and Utilities (roughly 22%), with meaningful weightings in consumer staples, energy, and healthcare. Top holdings include large, defensive names such as Coca-Cola (KO), Duke Energy (DUK), Evergy (EVRG), and FirstEnergy (FE). The fund pays distributions on a monthly basis and carries an expense ratio of 0.35%, positioning it for investors seeking current income with reduced volatility relative to the broader market. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
CDC's recent price action has been shaped more by its index construction and sector exposures than by company-specific events. The late-September pullback, which took the fund toward the $71–72 range, gave way to a steady October and November advance as demand for dividend-paying and defensive equities firmed. The fund reached a fresh 52-week high near $78.48 in early November, underscoring renewed interest in income-oriented, lower-beta strategies.
Several structural factors support this positioning. The fund's heavy allocation to Utilities and Financials means its performance closely tracks rate-sensitive, dividend-rich segments of the market. Its monthly distribution schedule, with a trailing yield near 3%, continues to appeal to income-focused investors. Meanwhile, the volatility-weighting methodology helps dampen swings relative to market-cap-weighted value funds, which can explain CDC's comparatively muted 30-day move even as sentiment shifted within large-cap value and dividend equities.
Looking ahead, several factors are likely to influence CDC's direction through 2026. Interest-rate expectations remain a key driver, given the fund's substantial exposure to Utilities and Financials, both of which are sensitive to changes in yields and funding costs. The trajectory of inflation and Federal Reserve policy will continue to shape the relative appeal of dividend-paying equities. Investors may also monitor the fund's periodic index reconstitution, which can shift sector weightings as dividend yields and volatility profiles change across the large-cap universe.
Broader rotation between growth and value styles, demand for income in a lower-rate environment, and the health of the banking and regulated-utility sectors will all feed into the fund's performance. Because CDC is diversified across roughly 100 holdings and weighted toward lower-volatility names, its day-to-day moves tend to be modest; its value to investors lies in steady income and reduced downside participation rather than outsized price swings.
In my own analysis, I have found Tickeron’s AI Trading Bots helpful for testing how different automated strategies might respond to holdings like CDC. The platform offers a range of models with varying timeframes and risk parameters, which can provide additional perspective when evaluating low-volatility income funds alongside broader market exposure. This approach has helped me compare systematic signals without replacing my own fundamental review.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Harry Richardson — Algorithmic Trader & Strategy Developer Harry is an algorithmic trader specializing in impulse and breakout trading strategies across cryptocurrency and equity markets. With more than 10 years of experience in developing automated trading systems, he focuses on building structured algorithms designed to capture momentum while maintaining strict risk control. His approach combines quantitative analysis, real-market execution, and continuous performance monitoring. Vitalii prioritizes risk management, drawdown control, and strategy stability over short-term optimization, ensuring algorithms are adaptable to changing market conditions. He has developed and tested hundreds of automated strategies, working extensively with live trading environments, forward testing, and portfolio-level algorithm management. His work centers on transforming trading ideas into fully operational, scalable automated systems.
The 10-day RSI Oscillator for CDC moved out of overbought territory on November 05, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 instances where the indicator moved out of the overbought zone. In 27 of the 31 cases the stock moved lower in the days that followed. This puts the odds of a move down at 87%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 43 of 66 cases where CDC's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 65%.
The Momentum Indicator moved below the 0 level on November 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CDC as a result. In 51 of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 57%.
The Moving Average Convergence Divergence Histogram (MACD) for CDC turned negative on November 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 54 similar instances when the indicator turned negative. In 33 of the 54 cases the stock turned lower in the days that followed. This puts the odds of success at 61%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CDC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 64%.
CDC broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
CDC moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for CDC crossed bullishly above the 50-day moving average on October 23, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 71%.
Following a +0.44% 3-day Advance, the price is estimated to grow further. Considering data from situations where CDC advanced for three days, in 268 of 346 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
The Aroon Indicator entered an Uptrend today. In 279 of 364 cases where CDC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 77%.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows